What is Nektar Therapeutics's D&A?

Nektar Therapeutics (NKTR) reported D&A of $151K in Q1 2026.

How has Nektar Therapeutics's D&A changed year-over-year?

Nektar Therapeutics's D&A decreased by 64.6% year-over-year, from $426K to $151K.

What is the long-term trend for Nektar Therapeutics's D&A?

Over 4 years (2021 to 2025), Nektar Therapeutics's D&A has grown at a -48.1% compound annual growth rate (CAGR), from $14.15M to $1.03M.

Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

Nektar Therapeutics NKTR D&A

D&A at other companies

Iovance Biotherapeutics, Inc.IOVA

$8.54M+5.9%

CRISPR TherapeuticsCRSP

$4.32M-8.8%

AmgenAMGN

——

Segments

By segment

See full

All Other Segments$121K-69.3%

Other financials

Income statement

See full

Revenue$10.9M+3.8%

Gross profit$21.8M+2.9%

Operating income-$39.1M+12.3%

Net income-$44.9M+11.7%

EPS (diluted)-$1.82+49.7%

Balance sheet

See full

Cash & equivalents$5.7M-20.0%

Total debt$83.2M-17.1%

Total equity$576.2M+4,094%

Total assets$763.3M+198%

Cash flow

See full

Operating cash flow-$44.3M+9.7%

CapEx$18.0K+800%

Free cash flow-$44.3M+9.7%

Valuation

See full

Market cap$2.25B+1,531%

Enterprise value$2.33B+874%

P/S40.5×+38.9×

Profitability

See full

Gross margin100%+31.2pp

Operating margin-242%—

Net margin-284.2%+937pp

FCF margin-366.6%+1,421pp

Returns & leverage

See full

Return on equity-53.6%-22.6pp

Debt / equity0.1×-7.2×

Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nektar Therapeutics's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Nektar Therapeutics's D&A?: Nektar Therapeutics (NKTR) reported D&A of $151K in Q1 2026.
How has Nektar Therapeutics's D&A changed year-over-year?: Nektar Therapeutics's D&A decreased by 64.6% year-over-year, from $426K to $151K.
What is the long-term trend for Nektar Therapeutics's D&A?: Over 4 years (2021 to 2025), Nektar Therapeutics's D&A has grown at a -48.1% compound annual growth rate (CAGR), from $14.15M to $1.03M.
What does D&A mean?: Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.